Rhumbline Advisers Catalyst Pharmaceuticals, Inc. Transaction History
Rhumbline Advisers
- $105 Billion
- Q2 2024
A detailed history of Rhumbline Advisers transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 323,769 shares of CPRX stock, worth $7.53 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
323,769
Previous 312,964
3.45%
Holding current value
$7.53 Million
Previous $4.99 Million
0.54%
% of portfolio
0.0%
Previous 0.0%
Shares
28 transactions
Others Institutions Holding CPRX
# of Institutions
300Shares Held
97.9MCall Options Held
29.2KPut Options Held
20.5K-
Black Rock Inc. New York, NY18.7MShares$435 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY9.13MShares$212 Million2.97% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.1MShares$188 Million0.0% of portfolio
-
State Street Corp Boston, MA6.03MShares$140 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$70.2 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.39B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...